1. OC-0167: Multi-modality centers associated with improved survival for patients with hepatocellular carcinoma. (April 2018) Authors: Jiang, J.; Ohri, N.; Kaubisch, A.; Kinkhabwala, M.; Guha, C.; Kabarriti, R. Journal: Radiotherapy and oncology Issue: Volume 127(2018)Supplement 1 Page Start: S86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO-1045: Addition of SBRT following TACE is associated with a survival benefit in Hepatocellular Carcinoma. (November 2020) Authors: Kabarriti, R.; Brodin, N.P.; English, K.; Ohri, N.; Kaubisch, A.; Kinkhabwala, M.; Kalnicki, S.; Guha, C.; Garg, M.K. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S556 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). (3rd August 2019) Authors: Moehler, M.; Heo, J.; Lee, H.C.; Tak, W.Y.; Chao, Y.; Paik, S.W.; Yim, H.J.; Byun, K.S.; Baron, A.; Ungerechts, G.; Jonker, D.; Ruo, L.; Cho, M.; Kaubisch, A.; Wege, H.; Merle, P.; Ebert, O.; Habersetzer, F.; Blanc, J.F.; Rosmorduc, Olivier Journal: Oncoimmunology Issue: Volume 8:Number 8(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗